

Shallu Kutlehria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/824072/publications.pdf>

Version: 2024-02-01

95
papers

3,185
citations

126907

33
h-index

182427

51
g-index

98
all docs

98
docs citations

98
times ranked

4626
citing authors

#	ARTICLE	IF	CITATIONS
1	Alginate-Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer Studies. PLoS ONE, 2013, 8, e53708.	2.5	189
2	Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. International Journal of Pharmaceutics, 2020, 586, 119560.	5.2	168
3	Nuclear receptor 4A (NR4A) family "orphans no more. Journal of Steroid Biochemistry and Molecular Biology, 2016, 157, 48-60.	2.5	149
4	Approaches to Improve the Oral Bioavailability and Effects of Novel Anticancer Drugs Berberine and Betulinic Acid. PLoS ONE, 2014, 9, e89919.	2.5	113
5	Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer, 2011, 71, 271-282.	2.0	106
6	Characterization and printability of Sodium alginate -Gelatin hydrogel for bioprinting NSCLC co-culture. Scientific Reports, 2019, 9, 19914.	3.3	106
7	Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer. PLoS ONE, 2011, 6, e17733.	2.5	93
8	Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems. Critical Reviews in Therapeutic Drug Carrier Systems, 2016, 33, 309-361.	2.2	72
9	Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. Journal of Controlled Release, 2013, 172, 86-95.	9.9	66
10	Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. Journal of Controlled Release, 2017, 246, 120-132.	9.9	61
11	Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation. Molecular Pharmaceutics, 2015, 12, 1105-1120.	4.6	60
12	Nanomiengel - A Novel Drug Delivery System for Topical Application - In Vitro and In Vivo Evaluation. PLoS ONE, 2014, 9, e115952.	2.5	58
13	Efficacy of Aerosolized Celecoxib Encapsulated Nanostructured Lipid Carrier in Non-small Cell Lung Cancer in Combination with Docetaxel. Pharmaceutical Research, 2013, 30, 1435-1446.	3.5	55
14	In vitro and in vivo evaluation of topical formulations of Spantide II. AAPS PharmSciTech, 2005, 6, E565-E572.	3.3	53
15	Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. Journal of Pharmaceutical Sciences, 2015, 104, 4417-4426.	3.3	53
16	Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. International Journal of Cancer, 2006, 118, 396-404.	5.1	51
17	Investigation of Follicular and Non-follicular Pathways for Polyarginine and Oleic Acid-Modified Nanoparticles. Pharmaceutical Research, 2013, 30, 1037-1049.	3.5	51
18	Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocrine-Related Cancer, 2015, 22, 831-840.	3.1	51

#	ARTICLE	IF	CITATIONS
19	NR4A1 Antagonists Inhibit β 21-Integrin-Dependent Breast Cancer Cell Migration. <i>Molecular and Cellular Biology</i> , 2016, 36, 1383-1394.	2.3	49
20	Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. <i>Drug Delivery</i> , 2016, 23, 1232-1241.	5.7	49
21	Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC). <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 153, 208-219.	5.0	49
22	Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers. <i>International Journal of Pharmaceutics</i> , 2015, 489, 106-116.	5.2	47
23	Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. <i>Journal of Controlled Release</i> , 2014, 184, 67-78.	9.9	46
24	Polysaccharide hydrogel based 3D printed tumor models for chemotherapeutic drug screening. <i>Scientific Reports</i> , 2021, 11, 372.	3.3	45
25	Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: Characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension. <i>AAPS PharmSciTech</i> , 2005, 6, E573-E585.	3.3	43
26	Epstein-Barr Virus LMP1 Promotes Syntenin-1- and Hrs-Induced Extracellular Vesicle Formation for Its Own Secretion To Increase Cell Proliferation and Migration. <i>MBio</i> , 2020, 11, .	4.1	43
27	Dermal Microdialysis Technique to Evaluate the Trafficking of Surface-Modified Lipid Nanoparticles upon Topical Application. <i>Pharmaceutical Research</i> , 2012, 29, 2587-2600.	3.5	42
28	High-throughput 3D bioprinting of corneal stromal equivalents. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2020, 108, 2981-2994.	3.4	41
29	Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. <i>Nanomedicine</i> , 2016, 11, 1377-1392.	3.3	40
30	Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. <i>Molecular Pharmaceutics</i> , 2016, 13, 2049-2058.	4.6	39
31	Formulation of topical ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strength. <i>Drug Delivery and Translational Research</i> , 2019, 9, 816-827.	5.8	37
32	Effect of jet fuels on the skin morphology and irritation in hairless rats. <i>Toxicology</i> , 2002, 175, 35-47.	4.2	35
33	Design, Synthesis of Novel Lipids as Chemical Permeation Enhancers and Development of Nanoparticle System for Transdermal Drug Delivery. <i>PLoS ONE</i> , 2013, 8, e82581.	2.5	35
34	Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 108, 168-179.	4.3	35
35	Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. <i>Pharmaceutical Research</i> , 2016, 33, 137-154.	3.5	32
36	Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. <i>Scientific Reports</i> , 2017, 7, 15824.	3.3	31

#	ARTICLE	IF	CITATIONS
37	Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 899-907.	2.4	30
38	Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. <i>Experimental Cell Research</i> , 2016, 346, 65-73.	2.6	29
39	Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 143, 156-167.	5.0	29
40	Long-circulating monensin nanoparticles for the potentiation of immunotoxin and anticancer drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 617-627.	2.4	28
41	In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDerm [®] (EPI-200) cultured human skin and hairless rats. <i>Toxicology Letters</i> , 2006, 167, 85-94.	0.8	27
42	Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer. <i>Pharmaceutical Research</i> , 2017, 34, 2371-2384.	3.5	27
43	Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models. <i>International Journal of Pharmaceutics</i> , 2021, 607, 120943.	5.2	27
44	Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer. <i>AAPS PharmSciTech</i> , 2018, 19, 792-802.	3.3	26
45	Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. <i>AAPS PharmSciTech</i> , 2018, 19, 3287-3297.	3.3	25
46	Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. <i>PLoS ONE</i> , 2017, 12, e0185116.	2.5	24
47	Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist: Spantide II. <i>Pharmaceutical Research</i> , 2004, 21, 108-113.	3.5	23
48	Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS). <i>Oncotarget</i> , 2016, 7, 31257-31269.	1.8	23
49	Encapsulation, Stability and In-vitro Release Characteristics of Liposomal Formulations of Colchicine. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 491-495.	2.4	22
50	Drug delivery strategies for chemoprevention of UVB-induced skin cancer: A review. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2018, 34, 60-68.	1.5	21
51	Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway. <i>Scientific Reports</i> , 2019, 9, 18177.	3.3	21
52	Tacrolimus Loaded PEG-Cholecalciferol Based Micelles for Treatment of Ocular Inflammation. <i>Pharmaceutical Research</i> , 2018, 35, 117.	3.5	20
53	Withaferin A ameliorates renal injury due to its potent effect on inflammatory signaling. <i>BioFactors</i> , 2019, 45, 750-762.	5.4	20
54	Theranostic tumor homing nanocarriers for the treatment of lung cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e1053-e1063.	3.3	19

#	ARTICLE	IF	CITATIONS
55	Alginate-Chitosan-Based 3D Cell Culture System as an In Vitro Tumor Model: An Important Tool in Cancer Research. <i>Methods in Molecular Biology</i> , 2016, 1379, 117-128.	0.9	18
56	Erlotinib-Valproic Acid Lipisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. <i>AAPS PharmSciTech</i> , 2019, 20, 135.	3.3	18
57	Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts. <i>Toxicology and Applied Pharmacology</i> , 2020, 401, 115112.	2.8	18
58	Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. <i>International Immunopharmacology</i> , 2022, 107, 108693.	3.8	18
59	Percutaneous permeation and skin irritation of JP-8+100 jet fuel in a porcine model. <i>Toxicology Letters</i> , 2001, 119, 133-142.	0.8	17
60	Stealth monensin immunoliposomes as potentiator of immunotoxins in vitro. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001, 52, 13-20.	4.3	17
61	CARP-1 Functional Mimetics Are a Novel Class of Small Molecule Inhibitors of Malignant Pleural Mesothelioma Cells. <i>PLoS ONE</i> , 2014, 9, e89146.	2.5	17
62	Combination of UVB Absorbing Titanium Dioxide and Quercetin Nanogel for Skin Cancer Chemoprevention. <i>AAPS PharmSciTech</i> , 2019, 20, 240.	3.3	17
63	Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 19-25.	2.4	16
64	The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-small Cell Lung Cancer. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1867-1882.	3.3	16
65	³¹ P solid-state NMR based monitoring of permeation of cell penetrating peptides into skin. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 190-199.	4.3	14
66	Withaferin A reverses bile duct ligation-induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2/Snail1, vimentin, and NF- κ B signaling. <i>BioFactors</i> , 2019, 45, 959-974.	5.4	14
67	Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. <i>Materials Science and Engineering C</i> , 2021, 119, 111460.	7.3	14
68	Trends in Drug Targeting for Cancer Treatment. <i>Drug Delivery</i> , 1996, 3, 289-304.	5.7	13
69	Mechanisms of Neuroblastoma Cell Growth Inhibition by CARP-1 Functional Mimetics. <i>PLoS ONE</i> , 2014, 9, e102567.	2.5	12
70	Percutaneous delivery of α -melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis. <i>Journal of Drug Targeting</i> , 2016, 24, 537-547.	4.4	12
71	Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 31-43.	3.3	12
72	Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine. <i>PLoS ONE</i> , 2016, 11, e0146804.	2.5	12

#	ARTICLE	IF	CITATIONS
73	Dermal microdialysis of inflammatory markers induced by aliphatic hydrocarbons in rats. <i>Toxicology Letters</i> , 2009, 185, 168-174.	0.8	11
74	Evaluation of self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity. <i>Journal of Controlled Release</i> , 2015, 213, 18-26.	9.9	11
75	CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. <i>Oncotarget</i> , 2016, 7, 73370-73388.	1.8	11
76	A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. <i>Oncotarget</i> , 2018, 9, 29680-29697.	1.8	11
77	Encapsulation, Stability, and In Vitro Release Characteristics of Liposomal Formulations of Stavudine (D4T). <i>Drug Delivery</i> , 1999, 6, 31-37.	5.7	10
78	Evaluation of Spray BIO-Max DIM-P in Dogs for Oral Bioavailability and in Nu/nu Mice Bearing Orthotopic/Metastatic Lung Tumor Models for Anticancer Activity. <i>Pharmaceutical Research</i> , 2015, 32, 2292-2300.	3.5	10
79	Effect of monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 819-825.	2.4	9
80	Opening Up the Optical Imaging Window Using Nano-Luciferin. <i>Pharmaceutical Research</i> , 2014, 31, 3073-3084.	3.5	9
81	Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 158, 172-184.	4.3	9
82	Role of In Vitro Models for Development of Ophthalmic Delivery Systems. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2021, 38, 1-31.	2.2	9
83	Comparison of the Transdermal Absorption of Nimesulide from Three Commercially Available Gel Formulations. <i>Drug Development and Industrial Pharmacy</i> , 2002, 28, 297-304.	2.0	8
84	Stability and degradation profiles of Spantide II in aqueous solutions. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 158-166.	4.0	8
85	Rapamycin Eyedrops Increased CD4+Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8890.	4.1	8
86	Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation. <i>Drug Delivery and Translational Research</i> , 2016, 6, 526-539.	5.8	7
87	Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 4215-4228.	1.1	7
88	Current Development of Oral Taxane Formulations: A Review. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2020, 37, 205-227.	2.2	6
89	Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45 β , integrin- β 5, β 25, β 21, and autophagy. <i>Drug Delivery and Translational Research</i> , 2022, , 1.	5.8	6
90	Whole-Eye Perfusion Model for Screening of the Ocular Formulations via Confocal Laser Scanning Microscopy. <i>AAPS PharmSciTech</i> , 2019, 20, 307.	3.3	5

#	ARTICLE	IF	CITATIONS
91	Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells. Journal of Pharmaceutical Analysis, 2021, 11, 799-807.	5.3	5
92	Nasal delivery of nanotherapeutics for CNS diseases: challenges and opportunities. Nanomedicine, 2021, 16, 2651-2655.	3.3	5
93	Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts. Pharmaceutics, 2022, 14, 1156.	4.5	4
94	Long circulating liposomes of 2â€²,3â€²-dideoxyinosine: Formulation and stability. Drug Delivery, 1996, 3, 279-287.	5.7	3
95	Sustained release dosage form of noscapine HCl using hot melt extrusion (HME) technique: formulation and pharmacokinetics. Drug Delivery and Translational Research, 2021, 11, 1156-1165.	5.8	3